Antiretroviral Therapy Perspective

 
 
  • CROI 2020 Read clinically focused news coverage of key developments from CROI 2020
  • Infectious Diseases in 2020: 5 Areas of Concern   Dr Paul Auwaerter discusses advances made in infectious diseases in 2019 and looks ahead at concerns for the new year.
  • Time to Rethink Renal Dosing of Lamivudine?   Dose reductions of lamivudine may not be necessary for all patients with mild to moderate renal impairment, says Dr Paul Sax.
  • ANAC 2019 Read clinically focused news coverage of key developments from ANAC 2019
  • USCA 2019 Read clinically focused news coverage of key developments from UCSA 2019
  • Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  • IAS 2019 Read clinically focused news coverage of key developments from IAS 2019
  • PrEP and Risk for Sexually Transmitted Infections   Dr Paul Sax shares what he thinks is most interesting and useful about the findings that STI risk is elevated in PrEP users.
  • CROI 2019 Read clinically focused news coverage of key developments from CROI 2019
  • Two- vs Three-Drug Initial Therapy for HIV   Dr Paul Sax describes the potential clinical implications of the GEMINI studies.
  • A Precaution About PrEP in HIV Prevention   PrEP can reduce new HIV infections if taken as directed. So why do PrEP failures occur?
  • Preventing HPV in Patients With HIV: New Guidelines A degree of synergism may exist between these two viruses, so prevention of HPV in patients with HIV is critical.
  • HIV 2018 Read clinically focused news coverage of key developments from HIV Glasgow 2018.
  • What Doravirine Offers Patients With HIV   Dr Paul Sax describes the trials that led to the approval of doravirine, which might offer some benefits to patients who can't tolerate other NNRTIs.
  • USCA 2018 Read clinically focused news coverage of key developments from UCSA 2018.
  • The New Single-Tablet HIV Drug: How We Might Use It   Dr Paul Sax comments on the place Symtuza? might occupy in the HIV treatment 'medicine chest.'
  • AIDS 2018 Read clinically focused news coverage of key developments from IAS 2018.
  • Here's What's New in the HIV Treatment Guidelines   Dr Paul Sax reports on a new recommended HIV treatment option and thanks Marty Hirsch for his skillful leadership of the guidelines working group.
  • This Novel, 1-Month Regimen to Prevent TB Is Practice-Changing   Dr Paul Sax reports on an intriguing two-drug regimen that could become the standard of care in preventing TB.
  • The SWORD Study: A New Two-Drug Combo for HIV   Dr Paul Sax highlights the findings of the SWORD study of dolutegravir-rilpivirine and outlines the clinical implications.